首页> 外文OA文献 >624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections

【2h】

624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections

机译：624 - 两项开放标签试验的比较表明RBX2660和RBX7455-Investigational Microbiota恢复治疗剂的相似6个月的结果用于预防复发性梭菌感染的灌肠或口腔胶囊

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ken Blount; Dale N. Gerding; Sahil Khanna; Darrell S. Pardi; Robert Orenstein; Erik R. Dubberke; Courtney R. Jones; Sarah Mische; Bill Shannon; Elena Deych;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection [J] . Bruce E Hirsch, Nimit Saraiya, Kaitlin Poeth, BMC Infectious Diseases . 2015,第1期

机译：使用口服胶囊对难治性梭状芽胞杆菌感染进行粪便来源的微生物群转移的有效性
2. Quality of Life Increased After Treatment for Participants in a Phase 2B Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of RBX2660 for Preventing Recurrent Clostridium difficile Infections [J] . Guthmueller Beth, Orenstein Robert, Dubberke Erik, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：治疗参与者的生活质量增加了A期2B的随机，双盲，安慰剂对照临床试验，用于预防复发性梭菌感染的RBX2660
3. Effect of Oral Capsule-vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection A Randomized Clinical Trial [J] . Kao Dina, Roach Brandi, Silva Marisela, JAMA: the Journal of the American Medical Association . 2017,第20期

机译：口服胶囊 - 与结肠镜检查的粪便微生物A移植对复发性蛋白梭菌感染的影响A随机临床试验
4. LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy Durability and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections [O] . Robert Orenstein, Sarah Mische, Sarah Mische, -1

机译：LB5。一个长期的未来：最终的为期2年的功效耐久性和微生物组变化的研究基于微生物菌的药物RBX2660用于复发性艰难梭菌感染的对照开放标签试验。
5. 29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection [O] . Nicky Ferdyan, Romeo Papazyan, Dana Walsh, 2020

机译：29.用基于研究微生物群的治疗RBX2660治疗胆酸组合物的快速恢复胆汁酸组合物用于复发性梭菌差异感染

624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections

著录项

引文网络

相似文献

相关主题

期刊订阅